Deciparticle™ Biomarker Framework: A New Dawn in Cancer Treatment
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and its partner, Sapu Nano, is making strides in cancer treatment with their innovative Deciparticle™ technology, which aims to enhance the efficacy of existing therapies. This collaboration recently unveiled groundbreaking biomarker data that reveals a specific molecular signature predictive of tumor response to Sapu003, an intravenous formulation of everolimus.
This research stands out as the first prospective biomarker framework tailored for intravenous everolimus, paving the way for targeted mTOR therapy to benefit patients who are likely to respond best to this innovative treatment.
Significance of the High-RICTOR / Low-RPTOR Gene-Expression Pattern
The analysis conducted by Oncotelic Therapeutics evaluated over 9,000 tumor samples from various cancer types. The findings indicate that tumors with a High-RICTOR / Low-RPTOR genetic expression show a significant reliance on mTOR signaling pathways. This makes these tumors more susceptible to treatment with Sapu003.
The biomarker data highlights:
- Patients whose tumors exhibit elevated RICTOR and suppressed RPTOR manifest increased dependency on mTORC2-AKT signaling pathways.
- Such tumors also show higher rates of glycolysis, increased metabolic stress markers, and diminished feedback mechanisms, making them prime candidates for intravenous everolimus therapy.
- This specific genetic profile is predominantly present in conditions such as HR+/HER2- breast cancer, lung adenocarcinoma, gastric cancer, renal cell carcinoma, ovarian cancer, and certain hematological malignancies.
Research across diverse datasets demonstrated that those with this genetic signature had notably poor survival outcomes with standard therapies yet showcased significant potential responsiveness to Sapu003.
IV Sapu003: Overcoming Traditional Treatment Barriers
Traditional oral formulations of everolimus have faced challenges, including inconsistent bioavailability and gastrointestinal side effects. These limitations hinder effective treatment outcomes. However, Sapu003 is designed to counter these obstacles effectively by providing:
- A remarkable 67-fold reduction in gastrointestinal accumulation, enhancing systemic effectiveness.
- Superior tissue penetration into metabolically active tumors.
- Preservation of pharmacologic specificity through unchanged intrinsic metabolism, minimizing adverse effects.
This novel approach allows for a more meticulous selection of patients based on their biomarkers, enhancing the likelihood of therapeutic success with mTOR inhibitors.
Insights from the Management Team
Dr. Seymour Fein, the Chief Medical Officer of Sapu Nano, emphasizes the significance of their findings: “We have lacked a robust patient selection strategy for mTOR inhibitors until now. The High-RICTOR/Low-RPTOR signature not only provides a molecular map of potential responders but also opens the door to a new therapeutic opportunity for mTOR-driven cancers.”
A Comprehensive Biomarker Discovery Methodology
The insights shared at this year's symposium stem from a multifaceted analysis that included:
- Utilizing over 9,000 TCGA and MET500 tumor transcriptomes to construct mTOR pathway co-expression networks.
- Identifying unique metabolic profiles of glycolysis-dependent tumors.
- Conducting survival modeling across a wide range of cancer types.
- Implementing predictive modeling regarding everolimus pathway dependency.
This intricate systems-biology methodology has empowered researchers to pinpoint mTORC2-dominant tumors, previously thought to be less amenable to treatment with oral everolimus, as potential candidates for the IV Sapu003 therapy.
Understanding Sapu Nano's Deciparticle™ Technology
Sapu003 encapsulates everolimus within Sapu Nano’s proprietary Deciparticle™ platform, engineered to address the common pitfalls of oral delivery. The design ensures consistent, predictable delivery of the drug while enhancing its bioavailability and efficacy.
About Oncotelic Therapeutics
Oncotelic Therapeutics is focused on advancing oncology drug development, emphasizing improved outcomes for cancer patients, especially in underserved areas like rare pediatric cancers. The company is investigating several therapies and innovative approaches, such as its joint ventures to foster growth and effectiveness in cancer care.
In addition to clinical advancements, Oncotelic is exploring next-generation treatments, adapting existing therapies for indications like Parkinson’s Disease and erectile dysfunction, showcasing its commitment to addressing a broad spectrum of healthcare issues. This includes developing novel solutions for female sexual dysfunction—an area with limited options but significant need.
Frequently Asked Questions
What is the Deciparticle™ framework?
The Deciparticle™ framework is a novel approach developed by Sapu Nano to enhance the delivery of cancer therapeutics by improving exposure and efficacy while reducing side effects.
How does IV Sapu003 differ from traditional therapies?
IV Sapu003 offers a more focused treatment method by utilizing biomarkers to identify patients who are likely to respond better, overcoming issues faced by oral formulations.
What cancers are primarily targeted by this research?
The research focuses on several cancers, including HR+/HER2- breast cancer, lung adenocarcinoma, gastric cancer, renal cell carcinoma, and ovarian cancer.
What are the potential benefits of targeting the High-RICTOR/Low-RPTOR signature?
Targeting this specific signature could lead to improved treatment outcomes for patients who previously had limited options, enhancing survival rates.
How can patients learn more about the treatments from Oncotelic?
Patients can contact Oncotelic directly through their investor relations email for more information on ongoing treatments and research initiatives.
